Hostname: page-component-745bb68f8f-cphqk Total loading time: 0 Render date: 2025-02-06T11:07:55.082Z Has data issue: false hasContentIssue false

Results for audiology and distortion product and transient evoked otoacoustic emissions in patients with systemic lupus erythematosus

Published online by Cambridge University Press:  26 October 2009

H Karabulut
Affiliation:
Otolaryngology Department, Ankara Keciören Research and Training Hospital, Turkey
M Dagli*
Affiliation:
Department of Otolaryngology, Ankara Numune Research and Training Hospital, Turkey
A Ates
Affiliation:
Department of Rheumatology, Ankara Numune Research and Training Hospital, Turkey
Y Karaaslan
Affiliation:
Department of Rheumatology, Ankara Numune Research and Training Hospital, Turkey
*
Address for correspondence: Dr Muharrem Dagli, Cemal Gursel Caddesi no 48/1, Cebeci 06600, Ankara, Turkey. Fax: 903124358832 E-mail: mdagli@hotmail.com
Rights & Permissions [Opens in a new window]

Abstract

The aim of the current study was to investigate hearing loss and cochlear function in patients with systemic lupus erythematosus, using audiology, distortion product otoacoustic emissions and transient evoked otoacoustic emissions.

Study design:

Prospective, case–control study.

Methods:

The study included 26 randomised patients with systemic lupus erythematosus (52 ears) and 30 healthy control subjects (60 ears). Pure tone audiometry was performed at 250 and 500 Hz and at 1, 2, 4, 6, 8, 10, 12, 14 and 16 kHz. Distortion product otoacoustic emissions and transient evoked otoacoustic emissions were measured using Biologic System equipment with Scout Acoustic Emissions System software.

Results:

The distortion product otoacoustic emission signal responses were significantly different only at 750 Hz, while the distortion product otoacoustic emission signal–noise ratios were significantly different at 750 Hz and 6 kHz (p < 0.05), comparing patients and controls. The transient evoked otoacoustic emission signal–noise ratios were significantly different at 2 and 3 kHz, comparing patients and controls (p < 0.05). The transient evoked otoacoustic emission total signal–noise ratios were significantly different, comparing patients and controls (p < 0.05). In addition, the pure tone audiometry thresholds were significantly different at 250 and 500 Hz and at 1, 2, 10 and 12 kHz, comparing patients and controls (p < 0.05).

Conclusion:

Our findings do not completely agree with those of previous temporal bone histopathological studies. However, our results do support a general picture of low frequency hearing loss in systemic lupus erythematosus patients. We consider these results to be related to endolymphatic and cochlear hydrops, and we suggest that electrocochleography could be performed in further studies for clarification of this subject.

Type
Main Articles
Copyright
Copyright © JLO (1984) Limited 2009

Introduction

Since the first description of autoimmune sensorineural hearing loss in 1979 by McCabe, many studies have investigated hearing in patients with autoimmune diseases, such as rheumatoid arthritis, ankylosing spondylitis, Behçet's disease, Sjögren's syndrome, polyarteritis nodosa and systemic lupus erythematosus (SLE).Reference McCabe1Reference Kastanioudakis, Ziavra, Voulgari, Exarchakos, Skevas and Drosos9

Systemic lupus erythematosus is a chronic, multisystem, autoimmune disorder characterised by production of autoantibodies and tissue deposition of immune complexes.Reference Sestak, Nath and Harley10 Inner ear involvement and sensorineural hearing loss (SNHL) have been widely reported in patients with autoimmune diseases such as SLE, in clinical, audiological and histopathological studies.Reference Karatas, Onat, Durucu, Baglam, Kanlikama and Altunoren8, Reference Kastanioudakis, Ziavra, Voulgari, Exarchakos, Skevas and Drosos9, Reference Fukushima, Fukushima, Cureoglu, Schachern and Paparella11Reference Yoon, Paparella and Schachern15 Many studies have found an association between SLE and SNHL, and several temporal bone histopathological studies have identified inner ear damage in patients with SLE.Reference Fukushima, Fukushima, Cureoglu, Schachern and Paparella11Reference Yoon, Paparella and Schachern15 The findings of audiometric studies have been inadequate to explain the origins of such hearing loss. Thus far, the mechanism of hearing loss in patients with SLE has not been further clarified.

The current study aimed to investigate the objective hearing status and outer hair cell function in patients with SLE, using audiometry, distortion product otoacoustic emissions (OAEs) and transient evoked OAEs.

Materials and methods

Patients

The study included 26 randomly selected patients with SLE (52 ears) who were diagnosed and treated in our hospital's rheumatology clinic, and 30 healthy control subjects (60 ears). Informed consent was obtained from all participants.

Disease activity was evaluated using the SLE Disease Activity Index.Reference Gladman, Urowitz, Kagal and Hallett16 Detailed information was obtained about possible aetiological factors leading to hearing loss (i.e. perforated tympanic membrane, ear surgery, cranial trauma, ototoxic drugs, noise exposure, Ménière's disease and metabolic diseases). No patients had a history of any of these factors.

Patients with any of the following were excluded from the study: (1) otoscopic evidence of a perforated tympanic membrane or other middle-ear pathology; (2) a ‘flat’ tympanogram, or absence of acoustic reflexes at 1 kHz with contralateral stimulation; (3) an air–bone gap of ≥5 dB at any frequency; (4) a sensorineural hearing loss more than 60 dB on audiologic evaluation; (5) DPOAE responses overlapping with noise floor.

Audiometry

The initial hearing examination included otoscopy, tympanography and complete audiological evaluation, including pure tone air- and bone-conduction audiometry and speech audiometry. Pure tone audiometry was performed at 250 and 500 Hz and at 1, 2, 4, 6, 8, 10, 12, 14 and 16 kHz, using an AC-40 diagnostic audiometer (Interacoustic, Denmark) in a sound-treated cabin. Normal middle-ear function was defined by immitance and acoustic reflex results using an Interacoustic AZ 26 clinical impedance meter.

The study included patients and controls with normal peak compliance, peak pressure, gradient, ear canal volume and acoustic reflexes, obtained by immitance measures, as defined by the American Speech Language and Hearing Association.17, 18

Otoacoustic emission testing

Both distortion product and transient evoked OAEs were measured using Bio-logic System equipment (Audx Scout Sport; Bio-logic Systems, Chicago, Illinois, USA) with Scout Acoustic Emissions System (version 3.45.00) software installed on the computer (which used a 2 GHz Pentium IV processor). Subjects were seated in a sound-proof room and asked to remain as quiet as possible during the test. Once the probe was placed with a good seal in the ear canal, the level of the two frequencies was set according to our protocol. Equilevel primary tones f1 and f2 was fixed at f1/f2 = 1.22, and f2 frequencies ranged from 750 Hz to 8 kHz; stimulus intensities used for recording distortion product OAEs were 65 dB for F1 and 55 dB for F2. The following protocol was selected for transient evoked OAE testing. Ear canal response monitoring was observed to check the fitting of the probe. The recording bandwidth was set between 1 and 4 kHz, with a repetition rate of 40. Stimulus and stimulus intensity was 80±4 dB. The test was stopped after a maximum of 2000 samples.

Statistical analysis

Statistical analyses were performed using the Statistical Package for the Social Sciences version 13.0 for Windows software. A p value of <0.05 was considered significant. Independent samples t testing was performed for overall comparisons of the groups (i.e. patients with SLE versus controls). The Mann–Whitney U test was used to compare the ages of patients and controls. The chi-square test was used to compare the genders of patients and controls. Pearson correlation analysis was used to investigate the relationship between quantitative variables.

Results

The mean age of patients with SLE was 36.3 (range 23–58) years; three were male and 23 were female. The mean age of the control group was 36.4 (range 26–55) years; two were male and 28 were female. Otoscopic examination was normal in all participants. There was no statistically significant difference between the ages and genders of the patient and control groups (p > 0.05).

The clinical features of the SLE patients are shown in Table I. No correlation was found between these disease parameters and distortion product OAE or transient evoked OAE findings. Twenty-one SLE patients were treated with quinine and prednisolone, and eight with azothioprine. There was no significant difference between the distortion product OAE and transient evoked OAE findings, comparing SLE patients taking and not taking medication (p > 0.05).

Table I Clinical features of SLE patients

SLE = systemic lupus erythematosus; min = minimum; max = maximum; SD = standard deviation; SLEDAI = SLE Disease Activity Index; RF = rheumatoid factor, ESR = erythrocyte sedimentation rate; CRP = C-reactive protein; C3 = Complement 3; C4 = Complement 4

Normal results for peak compliance, peak pressure, gradient, ear canal volume and acoustic reflexes were obtained by immitance measures in all patients and controls.

The pure tone audiometry results for patients and controls are shown in Table II. The pure tone thresholds of patients and controls were significantly different at 250 and 500 Hz and at 1, 2, 10 and 12 kHz (p < 0.05).

Table II Pure tone audiometry results

Freq = frequency; SD = standard deviation

The transient evoked OAE and distortion product OAE findings for patients and controls are shown in Tables III and IV. There was no statistically significant difference between the levels of noise floor, comparing patients and controls (p > 0.05). The distortion product OAE signal responses were significantly different only at 750 Hz, while the distortion product OAE signal–noise ratios were significantly different at 750 Hz and 6 kHz (p < 0.05), comparing patients and controls. The transient evoked OAE signal–noise ratio was significantly different at 2 and 3 kHz, comparing patients and controls (p < 0.05). The transient evoked OAE total signal–noise ratios of the patients and controls were also significantly different (p < 0.05).

Table III Transient evoked OAE results

OAE = otoacoustic emission; SNR = signal–noise ratio; SD = standard deviation

Table IV distortion product OAE results

OAE = otoacoustic emission; SNR = signal–noise ratio; SD = standard deviation

Discussion

Systemic lupus erythematosus is the prototypical autoimmune disease and is characterised by immune-mediated inflammation in multiple organ systems.Reference Sestak, Nath and Harley10 Immunological disturbances have been recognised to be associated with many causes of auditory dysfunction.Reference Stephens, Luxon and Hinchcliffe19 Some autoimmune diseases can cause SNHL, such as rheumatoid arthritis, ankylosing spondylitis, Behçet's disease, Sjögren's syndrome, polyarteritis nodosa and systemic lupus erythematosus.Reference Halligan, Bauch, Brey, Achenbach, Bamlet and McDonald2Reference Kastanioudakis, Ziavra, Voulgari, Exarchakos, Skevas and Drosos9

As with other autoimmune diseases, there have been reports of SNHL in patients with SLE.Reference Karatas, Onat, Durucu, Baglam, Kanlikama and Altunoren8, Reference Kastanioudakis, Ziavra, Voulgari, Exarchakos, Skevas and Drosos9, Reference Andonopoulos, Naxakis, Goumas and Lygatsikas20Reference Keithley, Chen and Linthicum23 In addition, several studies have reported aberrant temporal bone histopathological findings in SLE patients, namely, damage to the cochlea and other inner ear structures.Reference Fukushima, Fukushima, Cureoglu, Schachern and Paparella11Reference Yoon, Paparella and Schachern15

In their temporal bone histopathological study of a patient with SLE, Fukushima et al. reported that the cochlea, vestibule, semicircular canals and vestibular aqueduct were filled with dense fibrous tissue and new bone formation.Reference Fukushima, Fukushima, Cureoglu, Schachern and Paparella11 Sone et al. reported that the temporal bones of patients with SLE showed fibrous tissue, new bone formation replacing the entire cochlea, narrowed endolymphatic duct with fibrous proliferation, and cochlear hydrops.Reference Sone, Schachern, Paparella and Morizono12 Gussen described the temporal bone of a patient with polyarteritis nodosa, which showed perivascular infiltration of the labyrinthine artery, as well as fibrosis, bone formation and hydropic changes in the cochlea.Reference Gussen13

In these three studies, and others involving temporal bone histopathological examination in patients with SLE, the common findings were fibrous tissue, new bone formation and hydropic changes in the cochlea, and these patients had otological symptoms and sensorineural hearing loss. These findings are similar to labyrinthitis ossificans. The altered inner ear structures observed in temporal bone histopathological studies can be considered evidence of an association between hearing loss and SLE. However, these changes are not specific for SLE, and can also be observed after infectious labyrinthitis. The most commonly cited cause of labyrinthitis ossificans is viral or bacterial labyrinthitis.Reference Keithley, Chen and Linthicum23

  • Systemic lupus erythematosus (SLE) is a chronic, multisystem, autoimmune disorder characterised by production of autoantibodies and tissue deposition of immune complexes

  • Inner ear involvement and sensorineural hearing loss (SNHL) have been widely reported in autoimmune diseases such as SLE

  • This study aimed to investigate hearing loss and cochlear function in patients with SLE, using audiology, distortion product otoacoustic emissions (OAEs), and transient evoked OAEs

  • Low frequency SNHL seems to occur in SLE, and may be related to endolymphatic hydrops

Indeed, patients with SLE have a predilection for infection.Reference Petri24 Sone et al. reported that three of their seven SLE patients died of sepsis; furthermore, one patient had a clinical history of acute otitis media and ear discharge, and there was a history of gentamicin usage in two patients and furosemide usage in five patients.Reference Sone, Schachern, Paparella and Morizono12 Although new bone formation in the temporal bone is often associated with an infectious process, it may occur in advanced otosclerosis, trauma, tumours and autoimmune inner ear disease, and can lead to fibrosis and osteoneogenesis.Reference Keithley, Chen and Linthicum23 The cause of the inner ear changes observed in temporal bone histopathological studies of SLE patients is not clear, and infective agents or factors other than SLE cannot been excluded.

Conclusion

Our results do not completely agree with those of previous temporal bone histopathological studies of patients with SLE. However, our distortion product OAE, transient evoked OAE and audiology results do support a general clinical picture of low frequency hearing loss in such patients. These results may be related to endolymphatic and cochlear hydrops, and we suggest the use of electrocochleography for clarification of this subject in future studies.

References

1McCabe, BF. Autoimmune sensorineural hearing loss. Ann Otol Rhinol Laryngol 1979;88:585–9CrossRefGoogle ScholarPubMed
2Halligan, CS, Bauch, CD, Brey, RH, Achenbach, SJ, Bamlet, WR, McDonald, TJ et al. Hearing loss in rheumatoid arthritis. Laryngoscope 2006;116:2044–9CrossRefGoogle ScholarPubMed
3Dagli, M, Sivas Acar, F, Karabulut, H, Eryilmaz, A, Erkol Inal, E. Evaluation of hearing and cochlear function by DPOAE and audiometric tests in patients with ankylosing spondilitis. Rheumatol Int 2007;27:511–16CrossRefGoogle ScholarPubMed
4Eryilmaz, A, Dagli, M, Karabulut, H, Sivas Acar, F, Erkol Inal, E, Gocer, C. Evaluation of hearing loss in patients with ankylosing spondylitis. J Laryngol Otol 2007;121:845–9CrossRefGoogle ScholarPubMed
5Bayazit, YA, Yilmaz, M, Gunduz, B, Altinyay, S, Kemaloglu, YK, Onder, M et al. Distortion product otoacoustic emission findings in Behçet's disease and rheumatoid arthritis. ORL J Otorhinolaryngol Relat Spec 2007;69:233–8CrossRefGoogle ScholarPubMed
6Dagli, M, Eryilmaz, A, Tanrikulu, S, Aydin, A, Gonul, M, Gul, U et al. Evaluation of cochlear involvement by distortion product otoacoustic emission in Behçet's disease. Auris Nasus Larynx 2008;35:333–7CrossRefGoogle ScholarPubMed
7Hatzopoulos, S, Amoroso, C, Aimoni, C, Lo Monaco, A, Govoni, M, Martini, A. Hearing loss evaluation of Sjögren's syndrome using distortion product otoacoustic emissions. Acta Otolaryngol Suppl 2002;548:20–5CrossRefGoogle Scholar
8Karatas, E, Onat, AM, Durucu, C, Baglam, T, Kanlikama, M, Altunoren, O et al. Audiovestibular disturbance in patients with systemic lupus erythematosus. Otolaryngol Head Neck Surg 2007;136:82–6CrossRefGoogle ScholarPubMed
9Kastanioudakis, I, Ziavra, N, Voulgari, PV, Exarchakos, G, Skevas, A, Drosos, AA. Ear involvement in systemic lupus erythematosus patients: a comparative study. J Laryngol Otol 2002;116:103–7CrossRefGoogle ScholarPubMed
10Sestak, AL, Nath, SK, Harley, JB. Systemic lupus erythematosus: genetics of systemic lupus erythematosus: how far have we come? Rheum Dis Clin North Am 2005;31:223–44CrossRefGoogle ScholarPubMed
11Fukushima, N, Fukushima, H, Cureoglu, S, Schachern, PA, Paparella, MM. Hearing loss associated with systemic lupus erythematosus: temporal bone histopathology. Otol Neurotol 2006;27:127–8CrossRefGoogle ScholarPubMed
12Sone, M, Schachern, PA, Paparella, MM, Morizono, N. Study of systemic lupus erythematosus in temporal bones. Ann Otol Rhinol Laryngol 1999;108:338–44CrossRefGoogle ScholarPubMed
13Gussen, R. Polyarteritis nodosa and deafness. A human temporal bone study. Arch Otorhinolaryngol 1977;217:263–71CrossRefGoogle ScholarPubMed
14Jenkins, HA, Pollak, AM, Fisch, U. Polyarteritis nodosa as a cause of sudden deafness. A human temporal bone study. Am J Otolaryngol 1981;2:99107CrossRefGoogle ScholarPubMed
15Yoon, TH, Paparella, MM, Schachern, PA. Systemic vasculitis: a temporal bone histopathologic study. Laryngoscope 1989;99:600–9CrossRefGoogle ScholarPubMed
16Gladman, DD, Urowitz, MB, Kagal, A, Hallett, D. Accurately describing changes in disease activity in systemic lupus erythematosus. J Rheumatol 2000;27:377–9Google ScholarPubMed
17Anonymous. Guidelines for screening for hearing impairment and middle ear disorders. ASHA 1989;1:771Google Scholar
18Anonymous. Guidelines for screening for hearing impairment and middle ear disorders. Working Group on Acoustic Immittance Measurements and the Committee on Audiologic Evaluation. ASHA 1990;(suppl 2):1724Google Scholar
19Stephens, SDG, Luxon, L, Hinchcliffe, R. Immunological disorders and auditory lesions. Audiology 1982;21:128–48CrossRefGoogle ScholarPubMed
20Andonopoulos, AP, Naxakis, S, Goumas, P, Lygatsikas, C. Sensorineural hearing disorders in systemic lupus erythematosus. A controlled study. Clin Exp Rheumatol 1995;13:137–41Google ScholarPubMed
21Gomides, AP, do Rosário, EJ, Borges, HM, Gomides, HH, de Pádua, PM, Sampaio-Barros, PD. Sensorineural dysacusis in patients with systemic lupus erythematosus. Lupus 2007;16:987–90CrossRefGoogle ScholarPubMed
22Roverano, S, Cassano, G, Paira, S, Chiavarini, J, Graf, C, Rico, L et al. Asymptomatic sensorineural hearing loss in patients with systemic lupus erythematosus. J Clin Rheumatol 2006;12:217–20CrossRefGoogle ScholarPubMed
23Keithley, EM, Chen, MC, Linthicum, F. Clinical diagnoses associated with histologic findings of fibrotic tissue and new bone in the inner ear. Laryngoscope 1998;108:8791CrossRefGoogle ScholarPubMed
24Petri, M. Clinical features of systemic lupus erythematosus. Curr Opin Rheumatol 1995;7:395401CrossRefGoogle ScholarPubMed
Figure 0

Table I Clinical features of SLE patients

Figure 1

Table II Pure tone audiometry results

Figure 2

Table III Transient evoked OAE results

Figure 3

Table IV distortion product OAE results